Related Experiment Video

Updated: Mar 6, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.6K

Gastric cancer management: Kinases as a target therapy

Batoul Farran1, Susanne Müller2, Raquel C Montenegro3

  • 1Department of Structural and Molecular Biology, University College London, London, UK.

Clinical and Experimental Pharmacology & Physiology
|March 9, 2017
PubMed

Insights

Molecular diagnostics are revolutionizing oncology, especially for gastric cancer. This review explores targeted therapies and kinase inhibitors for gastric tumors, analyzing ongoing clinical trials for future directions.

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Genomics

Background:

  • Gastric cancer is a leading cause of cancer mortality worldwide.
  • Molecular diagnostics have identified key genetic alterations in gastric tumors.
  • Recurrent aberrations in kinase oncogenes (e.g., Her2, EGFR) are common in gastric cancer.

Purpose of the Study:

  • To review the mutational landscape of gastric cancer.
  • To examine the role of kinase inhibitors as targeted therapies.
  • To analyze ongoing clinical trials for novel gastric cancer inhibitors.

Main Methods:

  • Literature review of molecular diagnostics in oncology.
  • Analysis of genetic and epigenetic modifications in gastric cancer.
  • Examination of clinical trial data for kinase inhibitors.

Main Results:

  • Molecular diagnostics have improved understanding of gastric cancer.
  • Targeted therapies like trastuzumab have been approved.
  • Key kinase oncogenes represent targets for drug development.

Conclusions:

  • Targeted inhibition of specific oncogenes offers a promising therapeutic strategy for gastric cancer.
  • Ongoing clinical trials are evaluating novel kinase inhibitors.
  • Further research is needed to optimize targeted therapies and overcome resistance.
Keywords:
gastric cancerkinasesmonoclonal antibodiesprecision medicinesmall-molecule kinase inhibitorstargeted therapy

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
593